A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

Instituto Nacional de Cancer, Brazil20 enrolled

Overview

This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.

Progesterone receptor (PR) expression has been considered a biomarker of oestrogen receptor-α (ERα) activity. This longstanding relationship has been recently challenged and instead of being merely an ERα-induced gene target, PR may be a critical determinant of ERα activity. The functional significance of this steroid receptor crosstalk is regulation of a gene expression program associated with low tumorigenicity; hence, better disease outcome. Genomic alterations in the PR genomic locus seem to be a relatively common mechanism for reduction of PR expression, which may consequently lead to altered ERα chromatin binding and target gene expression patterns that increase breast tumorigenicity and confers a poor clinical outcome. This ERα-PR crosstalk may be directly influenced by many variables, including the relative receptor levels and the hormonal milieu. ER-positive advanced breast cancer is a heterogeneous group of diseases with considerable variability in outcome to a range of treatments. Prior response predicts the likelihood of subsequent benefit from another endocrine agent and this should be taken into account in the treatment decision process when assessing whether to prescribe a subsequent endocrine therapy. Despite the enormous progress made regarding the elucidation of breast cancer subgroups and their molecular drivers, most information comes from primary tumors. MA lacks cross-resistance and is active after acquired resistance to potent AI. This pilot trial evaluates in vivo MA modulation of steroidal receptors in advanced breast cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Neoplasm

Interventions

Megestrol Acetate 160Mg TabletDRUG

Megestrol acetate 160 mg PO daily

Anastrozole 1Mg TabletDRUG

Anastrozole 1 mg PO daily OR

Letrozole 2.5Mg TabletDRUG

Letrozole 2.5 mg PO daily OR

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic breast cancer with ER and/or PR positive (primary tumor) * Metastatic site amenable to biopsy Exclusion Criteria: * Platelet count below 100,000 / mm3 * Renal or hepatic impairment * Coagulation disorder

Locations (1)

Hospital do Cancer III

Rio de Janeiro, Brazil

RECRUITING

Outcomes

Primary Outcomes

Progression free survival

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months

Time frame: From date of randomization until disease progression or death due to any cause, assessed up to 18 months

Secondary Outcomes

Overall survival

From date of randomization until the date of death from any cause, assessed up to 18 months

Time frame: From date of randomization until death, assessed up to 18 months

Clinical benefit

Partial response and stable disease for more than 24 weeks, as per RECIST criteria, from date of randomization until the date of first documented progression or date of death, whichever came first, assessed up to 18 months

Time frame: Partial response and stable disease for more than 24 weeks, assessed up to 18 months

Central Contacts

Renata Obadia, RN

CONTACT

552132073810 robadia@inca.gov.br

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.